The innovative IdyllaTM KRAS Mutation Test, performed on the molecular diagnostic IdyllaTM platform (Biocartis, Mechelen, Belgium), enables the qualitative detection in human colorectal cancer FFPE material of 21 KRAS mutations being clinically relevant according to the latest CAP/AMP/ASCO, ESMO, and NCCN guidelines [23]. This evidence concerns the gene KRAS and colorectal cancer.